TET1 exerts an oncogenic role in AML as it upregulates the expression of oncogenes including HOXA9, MEIS1, and PBX3 [145] and downregulates the tumor suppressor targets such as miR-22 [146]. Here, TET1 is linked to acute myeloid leukemia.